Ovid Therapeutics Inc logo

Ovid Therapeutics Inc(OVID)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
SELL
SELL for 4 days
PROFIT SINCE LAST BUY
-20.14% ▼
LAST CLOSE
$2.2
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for OVID

11/20/2026: OVID (1-star) is a SELL. SELL for 4 days. Simulated Profits (-20.14%). Updated daily EoD!

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted treatments for rare neurological disorders and epilepsies. The company's main strengths lie in its specialized rare-disease pipeline and experienced management team, though it currently lacks commercial revenue-generating products. Its primary growth story revolves around advancing clinical candidates like OV329 toward regulatory approval and potential partnership milestones. Key risks include clinical trial uncertainty, high cash burn, and intense competition in the rare disease space. The stock suits risk-tolerant growth investors willing to monitor clinical readouts and regulatory catalysts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high potential capital appreciation tied to clinical pipeline milestones, offset by early-stage risk.
Momentum investorStrong fit while signal remains positiveCan experience sharp price movements driven by clinical trial readouts and regulatory announcements.
Value investorWeak fitLacks commercial revenue and traditional value metrics like earnings or book value safety.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for clinical development.
Low-risk investorWeak fitHigh clinical and regulatory binary risks make it unsuitable for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience sharp price swings around data readouts.
Valuation riskMedium / highValuations are driven by subjective pipeline expectations rather than current earnings or cash flows.
Competition risk (rare neurology drug developers)MediumCompeting therapies targeting similar rare neurological indications could capture market share.
Business qualityMediumThe company relies heavily on scientific research success rather than an established commercial franchise.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess depends on executing complex clinical trials and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 415.21M USD
Price to earnings Ratio -
1Y Target Price 6.15
Price to earnings Ratio -
1Y Target Price 6.15
Volume (30-day avg) 2.4M shares
Beta 0.24
52 Weeks Range 1.26 - 3.10
Updated Date 11/21/2026
52 Weeks Range 1.26 - 3.10
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.15

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -18.64%
Avg. Invested days 24
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
OVID receives a 3-star rating, supported by solid company fundamentals, and strong analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
OVID has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and strong ownership. In FY2025 versus FY2024, solid earnings growth (+34.1%) and strong revenue growth (+1181.3%) are partially offset by weak cash generation (FCF margin -528.6%), weak profitability (net margin -240.1%).

Financial Health Rating

★★★★★
OVID's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 43.8%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is OVID's strongest growth driver at +1181.3% FY2025 versus FY2024 (strong, 5 stars). Earnings growth (+34.1%, solid) and free-cash-flow growth (+31.6%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 84.0% and approximately 88.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.96% supports management-shareholder alignment.

Top 5 Institutional Investors

Jupiter Topco LLC 10.99%
Eventide Asset Management, LLC 6.26%
BlackRock Inc 5.74%
RA Capital Management, LLC 5.56%
Affinity Asset Advisors, LLC 5.38%

Unit Economics (Per $1K Revenue)

★★★★★
OVID generates approximately $959 of gross profit, $-5,852 of operating income, and $-5,286 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
OVID has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Collaboration and Licensing RevenuesUpfront licensing fees, research funding, and milestone payments from biopharmaceutical partners.Revenue is sporadic and depends on partnership agreements rather than steady product sales.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 1.79
Enterprise Value 317.39M
Price to Sales(TTM) 285.76
Enterprise Value 317.39M
Price to Sales(TTM) 285.76
Enterprise Value to Revenue 218.43
Enterprise Value to EBITDA -0.69
Shares Outstanding 188.73M
Shares Floating 167.32M
Shares Outstanding 188.73M
Shares Floating 167.32M
Percent Insiders 6.96
Percent Institutions 83.97

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.